MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.nucmedbio.2025.109019

Медицинская библиотека · Nuclear medicine and biology · 2025

Biodistribution of [18F]BCPP-BF in humans: a first-in-human positron emission tomography study.

Sato Kengo, Bunai Tomoyasu, Oda Akinori, Ohba Hiroyuki, Sano Yoshitaka, Tokui Aoi, Tsukada Hideo, Nishizawa Sadahiko, Harada Norihiro, Ouchi Yasuomi

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

INTRODUCTION

[18F]BCPP-BF and [18F]BCPP-EF are PET probes used to evaluate mitochondrial function by targeting MC-I. Clinical studies on [18F]BCPP-EF have been reported, particularly brain studies. However, no reports exist on the use of [18F]BCPP-BF in humans. Therefore, in this study, we aimed to apply [18F]BCPP-BF to humans for the first time to assess its safety and radiation dose. We also aimed to explore the whole-body distribution of both probes by comparing the data acquired from the same participants.

METHODS

Ten healthy participants underwent whole-body PET/CT measurements of [18F]BCPP-BF (117.0-153.8 MBq/body) for 90 min. Approximately 2-3 weeks after the measurements, the participants underwent [18F]BCPP-EF (109.2-158.8 MBq/body) measurements. Thirteen volumes of interest (VOIs) were manually drawn on the brain and peripheral organs using PET/CT images to evaluate the distribution and kinetics of the probes. The equivalent dose for each organ and the whole-body effective dose for each participant were calculated according to the Medical Internal Radiation Dose schema using OLINDA/EXM software.

RESULTS

The highest radiation doses from the administration of [18F]BCPP-BF were observed in the small intestine (65.5 ± 8.7 μGy/MBq), and the estimated effective dose (16.3 ± 2.3 μSv/MBq) was well-tolerated. There were no clinically significant safety concerns. A high accumulation of [18F]BCPP-BF was observed in the kidney, pancreas, and heart, consistent with the findings in previously reported animal studies. The distributions of both tracers were similar. However, the kinetics of [18F]BCPP-BF were different, with higher uptake and slower washout in the kidney and pancreas, and lower uptake and slower washout in the brain and liver, from those of [18F]BCPP-EF.

CONCLUSION

[18F]BCPP-BF is safe and acceptable for clinical use owing to its low toxicity and radiation dose. [18F]BCPP-BF and [18F]BCPP-EF generally exhibited similar whole-body distributions; however, their organ-specific kinetics differed slightly. The appropriate selection of these probes can provide a more accurate assessment of human mitochondrial function.

Для цитирования: Sato Kengo, Bunai Tomoyasu, Oda Akinori, Ohba Hiroyuki, Sano Yoshitaka, Tokui Aoi, Tsukada Hideo, Nishizawa Sadahiko, Harada Norihiro, Ouchi Yasuomi. Biodistribution of [18F]BCPP-BF in humans: a first-in-human positron emission tomography study.. Nuclear medicine and biology. 2025. DOI: 10.1016/j.nucmedbio.2025.109019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.